Unplanned Readmission among Patients with Advanced Cancer on Active Treatment: Multi-Center, Retrospective Study [0.03%]
晚期肿瘤接受治疗患者的非计划再入院：多中心回顾性研究
Sun Young Lee,Hong Jun Kim,Shin Hye Yoo et al.
Sun Young Lee et al.
Purpose: Unplanned readmissions of patients with cancer increase healthcare costs and disrupt care. Although well-studied in surgical oncology, data on patients receiving active treatment for advanced cancer remain limite...
A Prospective Study of Non‑Treating Medical Institution Use for Supportive Care During Adjuvant Chemotherapy After Curative Surgery (PRO-SUCCESS) [0.03%]
治愈性手术后辅助化疗期间非治疗医疗机构支持护理的前瞻性研究（PRO-SUCCESS）
So Yeon Oh,Kwonoh Park,Sang-Bo Oh et al.
So Yeon Oh et al.
Purpose: Patients undergoing adjuvant chemotherapy often utilize non‑treating medical institutions (NTMIs) for supportive care. We investigated utilization patterns and associated clinical factors. ...
Diagnostic Challenges and Clinical Implications of Microsatellite Instability/Mismatch Repair Deficiency in Solid Tumors [0.03%]
微卫星不稳定性/错配修复缺陷在实体瘤中的诊断挑战及临床意义
Yoonjin Kwak,Jeong Mo Bae,Hye Seung Lee
Yoonjin Kwak
The mismatch repair (MMR) system plays a crucial role in correcting replication errors; when the MMR system is deficient (dMMR), replication errors (particularly within microsatellites) accumulate throughout the genome, leading to microsate...
Platinum and 5-FU Salvage Therapy for Severe Liver Crisis in Metastatic Breast Cancer: Efficacy and Analysis of Prognostic Factors [0.03%]
铂类和氟尿嘧啶解救疗法治疗转移性乳腺癌严重肝危象的疗效及其预后因素分析
I-Wei Ho,Jiun-I Lai,Chun-Yu Liu et al.
I-Wei Ho et al.
Purpose: Metastatic breast cancer (MBC) with severe hepatic dysfunction due to liver crisis presents a significant treatment challenge, as conventional chemotherapy often requires dose modifications, leading to reduced ef...
Identification of Tumor Doubling Time-Related Subtypes and Construction of Risk Models to Predict Prognosis and Immunological Features in Breast Cancer [0.03%]
识别肿瘤倍增时间相关亚型并在乳腺癌中构建预测预后和免疫特征的风险模型
Yuehong Xu,Hongbo Li,Lulu Yang et al.
Yuehong Xu et al.
Purpose: Breast cancer (BRCA)'s molecular heterogeneity complicates prognosis and treatment. Tumor Doubling Time (TDT), a critical growth rate metric with clinical and prognostic significance, offers untapped potential as...
Immunosuppressive Tumor Microenvironment in Colorectal Cancer Lung Metastases: Implications for Recurrence After Metastasectomy [0.03%]
结直肠癌肺转移瘤的免疫抑制性肿瘤微环境及其转移术后复发的意义
Minsuk Kwon,Min-Kyue Shin,Minae An et al.
Minsuk Kwon et al.
Purpose: Colorectal cancer (CRC) lung metastases exhibit high recurrence rates after resection, underscoring the need for improved therapeutic strategies. This study aimed to characterize the tumor microenvironment (TME) ...
Redefining HER2 in Breast Cancer: From Conventional Positivity to Low and Ultralow in the New Era of Antibody-Drug Conjugates [0.03%]
乳腺癌HER2重定义：从传统阳性到低阳性和超低阳性——抗体药物偶联物新时代来临
Jiwon Koh,Seock-Ah Im
Jiwon Koh
Human epidermal growth factor receptor 2 (HER2) has evolved from a poor prognostic factor to one of the most impactful predictive biomarkers in oncology. The introduction of trastuzumab established HER2 as a binary determinant of therapy, w...
Utilization, Reimbursement, and Barriers to Accessing Sequencing Tests for Cancer Care in the Asia-Pacific Region: KSMO Initiatives to Address Cancer Care Inequity [0.03%]
亚太地区癌症护理中测序检测的使用、报销及准入障碍：KSMO为解决癌症护理不公平问题而开展的工作
Omali Pitiyarachchi,Aaron C Tan,Tawasapon Thambamroong et al.
Omali Pitiyarachchi et al.
Purpose: The Asia Pacific region is marked by healthcare diversity and economic disparity. Materials and methods: To understand the uti...
A Phase II Study of Bendamustine Plus Rituximab in Patients with Relapsed or Progressive Marginal Zone Lymphoma: KCSG LY14-09 [0.03%]
苯达莫司汀联合利妥昔单抗治疗复发或进展的边缘区淋巴瘤II期研究：KCSG LY14-09
Jeong-Ok Lee,Jinny Park,Hye Jin Kang et al.
Jeong-Ok Lee et al.
Purpose: This multicenter, phase II study examined the efficacy and safety of bendamustine plus rituximab in patients with relapsed or progressive marginal zone lymphoma (MZL). ...
ITGB2 Gene Gain as a Prognostic Marker for Early Recurrence in Luminal HER2-Negative High Proliferative Breast Cancer [0.03%]
ITGB2基因的获得作为高增殖性 luminal HER2阴性型乳腺癌早期复发的预后标志物
Chun-Yu Liu,Ji-Lin Chen,Yi-Fang Tsai et al.
Chun-Yu Liu et al.
Purpose: Early recurrence reflects aggressive disease and poor prognosis, with patterns varying across breast cancer subtypes. Early recurrence is a major challenge in luminal HER2-negative high proliferative breast cance...